The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes

A somatic mutation in the JH2 autoinhibitory domain of the Janus kinase 2 (JAK2) tyrosine kinase was recently described in polycythemia vera, essential thrombocythemia, and myelofibrosis with myeloid metaplasia. The prevalence of this mutation in either “atypical” myeloproliferative disorders (MPDs)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Steensma, David P., Dewald, Gordon W., Lasho, Terra L., Powell, Heather L., McClure, Rebecca F., Levine, Ross L., Gilliland, D. Gary, Tefferi, Ayalew
Formato: Artigo
Idioma:Inglês
Publicado em: The American Society of Hematology 2005
Assuntos:
Clinical Observations, Interventions, and Therapeutic Trials
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895198/
https://ncbi.nlm.nih.gov/pubmed/15860661
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2005-03-1183
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados